**Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards**

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

| Citation                  | Gupta, Tina, and Margo Hudson. 2017. “Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.” Journal of the Endocrine Society 1 (4): 247-259. doi:10.1210/js.2016-1055. http://dx.doi.org/10.1210/js.2016-1055. |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version         | doi:10.1210/js.2016-1055                                                                                                                                                                             |
| Citable link              | http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651920                                                                                                                                                   |
| Terms of Use              | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Hyperglycemia is a common issue affecting inpatient care. Although this is in part because of the higher rate of hospitalization among patients with preexisting diabetes, multiple factors complicate inpatient glucose management, including acute stress from illness or surgery, erratic dietary intake, and contribution of medications. It has been repeatedly demonstrated that poorly controlled blood glucose levels are associated with negative clinical outcomes, such as increased mortality, higher rate of surgical complications, and longer length of hospital stay. Given these concerns, there has been extensive study of the optimal strategy for management of glucose levels, with the bulk of existing literature focusing on insulin therapy in the intensive care unit setting. This review shifts the focus to the general adult medical and surgical wards, using clinical guidelines and sentinel studies to describe the scientific basis behind the current basal-bolus insulin-based approach to blood sugar management among noncritically ill inpatients. Patient-centered clinical trials looking at alternative dosing regimens and insulin analog and noninsulin agents, such as glucagon-like peptide-1 agonist therapies, introduce safe and effective options in the management of inpatient hyperglycemia. Data from these studies reveal that these approaches are of comparable safety and efficacy to the traditional basal-bolus insulin regimen, and may offer additional benefit in terms of less monitoring requirements and lower rates of hypoglycemia. Although existing data are encouraging, outcome studies will be needed to better establish the clinical impact of these more recently proposed approaches in an effort to broaden and improve current clinical practices in inpatient diabetes care.
Evaluation and Survival Using Glucose Algorithm Regulation study, an intravenous insulin infusion is successful at maintaining glucose in a predetermined range in the ICU; however, it is not practical outside of a critical care setting because of the intensity of nursing support required [11]. In this review, we will focus on use of insulin and noninsulin agents for glucose control in the general adult medical and surgical wards, highlighting outcome studies, treatment trials, and remaining controversies in management. Specific issues addressed here will include the relationship of glucose levels to outcomes, ideal targets for glucose, and optimal medical management of blood glucose levels.

1. Historical Perspective

In a 2004 seminal review by Clement et al. [6], the question of what constitutes optimal glucose control was investigated. The concept of blood glucose threshold levels was addressed in terms of mortality outcomes across different medical and surgical fields. Data collected by Umpierrez et al. [12] from 1886 admissions found that 12% of these patients demonstrated new hyperglycemia (defined by fasting blood glucose $\geq 126$ mg/dL or random blood glucose $\geq 200$ mg/dL on two or more occasions and no history of diabetes), a finding that was associated with an 18-fold increase in inpatient mortality compared with normoglycemic patients. These patients were also found to have longer hospital stays, greater likelihood of need for a critical care setting, and higher rate of transitional care. A meta-analysis by Capes et al. [13] compared the relative risk of inpatient mortality after myocardial infarction in patients with and without diabetes in relation to admission blood glucose levels. Patients with diabetes with admission glucose $\geq 180$ mg/dL were found to have a moderately increased relative risk at 1.7 [95% confidence interval (CI), 1.2 to 2.4] for inpatient mortality compared with those patients with diabetes and glucose values below this threshold. Among patients without diabetes, admission glucose values of 110 to $\geq 144$ mg/dL were associated with a substantial increase in relative risk of inpatient mortality (3.9; 95% CI, 2.9 to 5.4). Of note, the ranges of blood glucose used in these results were based on varying cutoffs among studies included in the meta-analysis.

Hyperglycemia has also been found to correlate with postoperative complications, and studies have shown that controlling glucose levels improves morbidity and mortality among surgical patients [14–20]. Based on this known association, Wang et al. [21] conducted a cohort study with >6600 patients undergoing general and vascular surgery to investigate a correlation between preoperative glucose and postoperative infection. The sample excluded known patients with diabetes and those with preoperative sepsis. The study authors found that rates of infection after surgery were significantly lower in those patients with preoperative glucose levels within a lower range (5.62%, $P < 0.001$ for glucose of 70 to 99 mg/dL) than in those with levels of 100 to 139 mg/dL (9.33%) and 140 to 179 mg/dL (10.16%). Although these data, and those from the Capes et al. review [13], are observational, and thus subject to the usual limitations, they do offer a solid physiologic rational for the strong association between hyperglycemia and poor outcomes. In addition, this association is consistent across patient populations and disease states and includes endothelial dysfunction, impaired tissue perfusion, prothrombotic state, increased platelet aggregation, and left ventricular dysfunction [22–26].

2. Why Insulin?

When considering how to manage hyperglycemia, insulin is generally accepted as the primary therapy for achieving glucose control [6] based on several studies showing an association between insulin treatment and improved patient outcomes [18, 27]. The traditional thought has been that this was related to the effect on blood glucose levels; however, small supporting studies have since shown pleiotropic effects independent of glucose lowering results, including improved myocardial perfusion [28], decreased blood pressure [29, 30], and decreased heart failure [31]. With knowledgeable prescribing providers, insulin can be matched to...
rapidly changing patient needs because of dose flexibility and multiple types with different durations of action—especially in the setting of variable and unpredictable nutrition. Because insulin does not have drug interactions, it is particularly desirable in the hospital where other medications are being added or discontinued rapidly.

3. Improving on Tradition

Insulin is often described in terms of its pharmacokinetic and pharmacodynamic properties and typically categorized as basal, prandial, or correctional. Although basal insulin, meant to match endogenous insulin production in a fasting state, describes long-acting formulations with minimal daily variation, prandial and correctional insulins are short-acting and are used to address glucose peaks that occur after food ingestion or to correct hyperglycemia to an ideal range, respectively [32, 33].

Outside of the ICU, glucose has frequently been managed with correctional insulin only (the traditional sliding scale), rather than in combination with basal insulin and prandial insulin [34]. However, this may not be the most appropriate approach for inpatient hyperglycemia management, a claim supported by findings from a prospective cohort study by Queale et al. [35]. Using data from 171 medical inpatients with diabetes, study investigators discovered that individuals receiving monotherapy with correctional insulin had a threefold higher risk of hyperglycemia than those not on any pharmacologic diabetes treatment ($P < 0.05$). Although conclusions are limited from this observational study, the data did demonstrate a lack of benefit from regimens using only sliding-scale insulin, and subsequent studies have since provided additional evidence supporting newer, alternative regimens.

One such study is the 2007 Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial), a prospective controlled investigation by Umpierrez et al. [36] comparing the efficacy and safety of a basal-bolus regimen with the traditional sliding-scale regimen using correctional doses of insulin in 130 insulin-naive patients with known type 2 diabetes admitted to general medicine services (ICU patients were excluded). Patients were randomized to a regimen consisting of daily glargine and mealtime glulisine with correctional glulisine (basal bolus) using weight-based initial dosing and a titration algorithm or glulisine only for correction of blood sugars according to a sliding scale insulin (SSI). The study authors found that those patients in the basal-bolus group had lower fasting blood sugars ($147 \pm 36 \text{ mg/dL}$ vs $165 \pm 41 \text{ mg/dL}$, $P < 0.01$), lower lengths of stay, and greater prevalence of achieving goal glucose levels (blood sugar 70 to 140 mg/dL) with 66% at goal within the basal-bolus regimen as compared with 38% in the SSI group. Incidence of hypoglycemia, defined as blood sugar $<60 \text{ mg/dL}$, was equal between the two groups and acceptably low at two patients each. Although admittedly underpowered to determine change in other outcomes, such as mortality, this study did demonstrate greater glycemic control without increased hypoglycemia in the basal-bolus group.

A follow-up study in 2011 by Umpierrez et al. [7] again compared the efficacy of a basal-bolus regimen to a sliding-scale protocol, this time among surgical patients, with end points including postoperative complications (wound infection, pneumonia, bacteremia, and respiratory or acute renal failure) in addition to daily blood glucose levels. Unlike those patients in the original RABBIT 2 trial, participants in RABBIT 2 surgery were not necessarily insulin-naive. Target glucose range was 100 to 140 mg/dL in this study. In addition to finding lower blood glucose levels in the basal-bolus group ($145 \pm 32 \text{ mg/dL}$ compared with $172 \pm 47 \text{ mg/dL}$ in the sliding-scale group), study authors found a substantial reduction in composite outcomes, which included pneumonia, bacteremia, wound infection, and respiratory and renal failure, from those on the sliding-scale regimen (24.3%) compared with those on the basal-bolus regimen (8.6%) ($P = 0.003$). This is the only randomized trial looking at hard outcomes beyond glucose control outside of the ICU setting. There was a higher incidence of mild hypoglycemic events in this study compared with the RABBIT 2 medicine trial, with 23.1% of patients in the basal-bolus group and 4.7% of patients in the sliding-scale group having a recorded glucose level $<70 \text{ mg/dL}$ ($P < 0.001$). Severe hypoglycemia
(glucose <40 mg/dL) occurred in 3.8% of the basal-bolus group and in none of the SSI group. Possible explanations for this higher rate compared with the medicine trial include reduced nutritional intake among surgical patients, and most patients in the surgical trial were on a higher total daily dose of insulin (0.5 U/kg/d compared with 0.4 U/kg/d, respectively) than most of the patients in the medicine trial.

In the Basal Plus trial, Umpierrez et al. [37] investigated the necessity of scheduled prandial insulin for inpatient glycemic control. The study looked at 375 patients admitted to medical or surgical services with a known history of type 2 diabetes who were randomly assigned to three treatment arms: a basal-bolus regimen with scheduled premeal and corrective short-acting glulisine in addition to long-acting glargine, a basal plus regimen consisting of glargine along with corrective glulisine, and a third arm using a corrective scale for blood glucose levels >140 mg/dL without basal insulin. Patients were targeted to blood glucose goal range of 100 to 140 mg/dL, and if treatment failure was encountered in the basal plus or corrective scale group (defined as a mean daily blood glucose >240 mg/dL or consecutive blood glucose levels >240 mg/dL), patients were advanced to the basal-bolus regimen. The study found that both the basal-bolus and basal plus regimens had lower mean daily blood glucose levels than the corrective-only regimen ($P = 0.04$) and that the improvement in mean daily blood glucose after the first day of treatment was similar between the two basal-containing regimens. These two regimens also were found to have less treatment failure than the corrective regimen. There was no difference among the three groups regarding incidence of severe hypoglycemia (defined as blood glucose <40 mg/dL); however, mild hypoglycemia (blood glucose <70 mg/dL) was higher in the basal-bolus regimen (16%) than the basal plus (13%) and corrective-only regimens (3%, $P = 0.02$). Given the similar efficacy between the two basal-containing regimens, and overall improvement in glycemic control relative to the corrective insulin regimen, the study concluded that basal insulin should be included in glucose treatment plans and that a modified regimen such as basal plus offers similar control compared with the traditional basal-bolus regimen.

Haw et al. went on to investigate the effect of these two regimens on glycemic variability (GV), calculated using the mean daily standard deviation of blood glucose values, the mean daily range of blood glucose (average daily GV), and the mean amplitude of glycemic excursions [38–41] in a post hoc analysis of the Basal Plus trial [42]. Looking at data from 279 general medicine and surgery patients, the analysis revealed no substantial difference in GV between the basal plus and basal-bolus groups. Interestingly, surgical patients in the basal-bolus group compared with their surgical cohort in the basal plus group were found to have a statistically significant higher GV. Of note, the degree of GV did not seem to correlate with the rate of hospital complications; therefore, its clinical significance is not established.

### 4. Human or Analog

Recombinant human insulins are available in short-acting and intermediate-acting formulations. However, they are not as well matched to basal and prandial needs as the newer analog insulins, which are available in more rapid-acting and longer-acting formulations, the latter of which avoids the insulin peak that often complicates glucose management. Analog insulins are, however, more expensive than their human insulin counterparts, thus creating a dilemma for hospitals. These different factors must all be considered to determine the best types of insulin for inpatient use. In a multicenter trial of 130 patients admitted to a general medicine service, the safety and efficacy of a regimen using insulin analogs was compared with one using human insulins [43]. For this study, patients with type 2 diabetes and blood glucose levels between 140 and 400 mg/dL were randomized to either a basal-bolus (analog insulins) regimen with daily detemir and premeal aspart or a split-mixed protocol using twice-daily injections of neutral protamine Hagedorn (NPH) and regular insulin (human insulins). Initial dosing was based on a weight-based regimen for both groups. Patients were restricted to those with blood glucose levels between 140 and 400 mg/dL, at least a 3-month known history of type 2 diabetes, and absence of diabetic ketoacidosis. By treating to goal blood
glucose levels between 60 (threshold for hypoglycemia) and 140 mg/dL, study authors discovered similar glycemic improvement between the detemir and NPH groups, with pretreatment blood glucose levels of $228 \pm 54$ mg/dL and $223 \pm 58$ mg/dL ($P = 0.61$) improving to $160 \pm 38$ mg/dL and $158 \pm 51$ mg/dL ($P = 0.8$), respectively, after the first day of therapy. In addition, no significant difference was found between the two groups in terms of number of patients experiencing an episode of hypoglycemia ($P = 0.20$) and frequency of hypoglycemic blood glucose readings ($P = 0.86$). Based on these findings, the study authors concluded there were no statistical differences in efficacy, as measured by improvement in mean daily blood glucose levels, or safety, as determined by hypoglycemia incidence, between the analog regimen of detemir/aspart and a human insulin regimen of NPH/regular. This study had important implications for hospitals concerned with higher cost of analog insulins.

5. Hypoglycemia

Turchin et al. [44] looked at the effect inpatient hypoglycemic events had on patients in a 2009 retrospective, cohort study of 4368 admissions in 2500 patients with diabetes. Both the number and severity of hypoglycemic events, defined as a glucose level $< 50$ mg/dL, were evaluated, as were length of stay and mortality (inpatient and 1-year after discharge). The study found a 7.7% incidence of hypoglycemia among the admissions and, through a multivariable analysis, discovered that each additional day with hypoglycemia was associated with an 85.3% increase in odds of an inpatient death ($P = 0.009$); this risk rose three times for every 10 mg/dL decrease in the lowest blood glucose during hospitalization ($P = 0.0058$). There was also a 65.8% increase in odds of death within 1 year after discharge ($P = 0.0003$) with each additional day of hypoglycemia. As for length of stay, this was increased by 2.5 days for each day with hypoglycemia ($P < 0.0001$). Further, multiple studies have also demonstrated a positive association between mortality and hypoglycemia [45–47]. Although the mechanism behind the relationship between hypoglycemia and mortality remains unclear, possible explanations include the proinflammatory state of hypoglycemia and sympathetic nervous stimulation, subsequently leading to arrhythmias and ischemia [46, 48, 49]. Furthermore, the context of hypoglycemia may be important, with several studies finding higher mortality rates associated with spontaneous hypoglycemia compared with that induced with insulin therapy [50–52]. This suggests underlying severe illness, such as multiorgan failure, is contributing to these higher rates. Finally, in severe hypoglycemia, neurologic complications such as seizure with aspiration may cause additional damage [53].

A retrospective cohort study by Garg et al. [54] went on to investigate whether the relationship between hypoglycemia and mortality was associated with insulin use. Using inpatient data from 2008 to 2010, the study authors examined the prevalence of mortality across four separate groups, according to presence of hypoglycemia (defined as blood sugar $\leq 50$ mg/dL) and treatment with insulin. Study findings were notable for a significantly higher mortality among those patients with insulin-treated hypoglycemia compared with the insulin-treated controls (20.3 vs 4.5%, $P < 0.0001$). Noninsulin-treated hypoglycemia was similarly associated with greater mortality than seen among noninsulin-treated controls (34.5 vs 1.1%, $P < 0.0001$). Interestingly, those in the noninsulin-treated hypoglycemia group experienced higher mortality rates than those in the insulin-treated hypoglycemia group ($P < 0.0001$); however, the opposite was found among the controls, with significantly lower mortality in the noninsulin-treated control group compared with the insulin-treated control group ($P < 0.0001$). These findings demonstrate an association between hypoglycemia and mortality and go on to illustrate a stronger effect of spontaneous (noninsulin treated) hypoglycemia on mortality compared with insulin-associated hypoglycemia. This latter finding, which has been described previously, may be the result of other contributing factors, such as malnutrition or malignancy, in cases of spontaneous hypoglycemia that could account for a worse prognosis.

The risk of hypoglycemia in relation to the particular regimen insulin dosing was then assessed in a retrospective, case-control study by Rubin et al. [55] in 2011. Of 1990
hospitalized patients with a diagnosis of diabetes selected for the study, half were defined as cases, as determined by a point-of-care (POC) glucose \(< 70\) mg/dL after the first 24 hours of admission. Controls were defined by a POC glucose \(\geq 70\) mg/dL and matched to each case on the basis of hospital day of hypoglycemia, age, sex, and body mass index. The insulin doses administered during the 24-hour period prior to hypoglycemia in the cases, and matched POC in the controls, were then evaluated in terms of dose per body weight and type of insulin exposure. The latter was categorized among four different regimens: glargine plus any other insulin, NPH plus any other insulin, lispro and/or regular insulin only, and no insulin. The authors found that the odds of hypoglycemia (adjusted for insulin regimen, SSI use, and albumin, creatinine, and hematocrit) were not increased by increasing insulin dosing within a range of \(0.2\) to \(0.6\) U/kg/d. However, odds of hypoglycemia were higher among patients receiving insulin doses \(> 0.6\) U/kg/d.

6. Noninsulin Agents: Why Not?

In addition to these observed benefits, insulin has also been the longstanding preferred agent to treat inpatient hyperglycemia because of limitations of other therapies. Metformin, although a recommended first-line medication for treatment of type 2 diabetes [56], is discouraged in patients with conditions that predispose toward central hypoxia, such as pulmonary, cardiac, or renal impairment, because of the concern for increased risk of lactic acidosis, a rare but serious complication of metformin therapy [57]. Other contraindications to metformin use include severe liver disease, alcohol abuse, and concurrent use of potentially renal toxic intravenous radiographic contrast agents, all of which limit its applicability in the hospital setting [58, 59].

Sulfonylureas are another commonly used oral agent for type 2 diabetes; however, because insulin secretagogues, these medications can cause hypoglycemia, and unlike insulin, their dosing is less flexible, and onset and duration of action can be less predictable. Considering the risk of hypoglycemia is increased in those with erratic or poor oral intake, or those with hepatic or renal impairment, all of which may be encountered more frequently in hospitalized patients, sulfonylureas are not considered preferred agents for inpatient glycemic control [2, 56, 57]. Thiazolidinediones, which act as insulin sensitizers, have a substantial delay in onset of action [56]. These drugs are associated with peripheral edema and precipitation or exacerbation of heart failure [57]. Considering these described limitations for treatment alternatives, insulin established itself as the recommended and most widely used agent for glucose management in the hospitalized setting [6].

7. Newer Noninsulin Agents: Maybe?

Given the detrimental effects of hypoglycemia related to insulin therapy and the complexity of administration, studies have also been conducted looking at the role of alternatives to insulin for inpatient diabetes management. Although studies looking at clinical outcomes with incretin therapy in the hospitalized setting are limited, existing trial data suggest this may be a useful addition to or substitute for insulin treatment. A pilot study in 2013 investigated the safety and efficacy of sitagliptin, a DPP4 inhibitor, compared with insulin regimens in general medical/surgical wards [60]. In this trial, 90 patients with diabetes were randomized to one of three arms: sitagliptin only, sitagliptin with daily glargine, and a traditional basal-bolus regimen with daily glargine and bolus lispro insulin. In addition, patients across all three arms received correctional lispro insulin according to a standard sliding scale. Similar improvement was seen across all three groups, including no differences in mean daily blood glucose levels after the first day of treatment \((P = 0.23)\) and number of readings within goal blood glucose of \(70\) to \(140\) mg/dL \((P = 0.53)\). There was no difference in length of stay \((P = 0.78)\) or hypoglycemic events \((P = 0.86)\) among the three arms, and total daily dose and number of injections were significantly less in the sitagliptin and insulin arm compared with the traditional basal-bolus group \((P < 0.001)\). Of note, inclusion in this study was limited to
patients treated for their diabetes with diet alone, oral agents, or insulin therapy at a daily dose ≤0.4 U/kg, thus narrowing the clinical applicability of the study findings.

More recently, Pasquel et al. [61] went on to further investigate the role of sitagliptin therapy in inpatient management of glucose control among inpatients with type 2 diabetes admitted to general medicine and surgery wards. In this randomized controlled trial, 277 patients were assigned on a 1:1 basis to either the sitagliptin-basal group (daily sitagliptin plus daily glargine) or a more conventional basal-bolus group (mealtime lispro or aspart plus daily glargine). Study investigators found that patients in the sitagliptin-basal group had a similar mean daily blood glucose concentration as those in the basal-bolus group (172 vs 170 mg/dL, respectively), with nonsignificant differences in treatment failure or hypoglycemia rate between the two groups, thus meeting the noninferiority threshold for this trial.

The utility of incretin-based therapy is further supported in an editorial by Schwartz and DeFronzo in 2013 addressing the use of glucagon-like peptide-1 (GLP-1) receptor agonist therapy [62]. Although long considered the gold standard for inpatient management of diabetes by many, Schwartz and DeFronzo proposed that the association of insulin with hypoglycemia and data showing lack of mortality benefit call this role of insulin into question. They argue that, in contrast, GLP-1 agonist therapy would not carry a similar hypoglycemia risk because of the glucose-mediated stimulation of insulin release and inhibition of glucagon secretion [63, 64]. Of note, this opinion is founded on studies among critically ill patients, and its relevancy in the non-ICU setting is less clear.

In terms of efficacy, multiple studies have found treatment with GLP-1 or GLP-1 receptor agonist therapy is comparable with insulin in terms of glycemic control, and even allows for lower insulin dosing if these medications are used concurrently [65–69]. Studies also suggest an impact of GLP-1 therapy on several cardiovascular parameters, including improved left ventricular ejection fraction and endothelial function [70–72]; however, other studies have failed to show a similar effect on left ventricular ejection fraction [69, 73]. Given the dearth of trials looking at clinical outcomes, further study is needed looking at GLP-1 receptor agonist therapy among hospitalized patients. Thus far, however, data regarding incretin-based therapy support the use of these agents for achieving glycemic control in the inpatient setting, especially considering the additional benefit of reduced provider burden in terms of less frequent glucose monitoring and dose titrations [74].

8. Special Circumstances

The use of enteral or parental feeding poses an additional challenge to inpatient glycemic control, with hyperglycemia commonly associated with these forms of nutrition. This has, in turn, been linked to greater inpatient mortality as demonstrated by a prospective study by Olveira et al. [75], which looked at mortality rates among noncritically ill inpatients across 19 hospitals in Spain receiving total parenteral nutrition (TPN). After adjusting for multiple factors, including nutritional state, presence of diabetes, and insulin or steroid use, logistic regression analysis of data collected from 605 patients showed that mean blood glucose levels >180 mg/dL while receiving TPN were associated with a 5.6 times greater mortality risk than levels <140 mg/dL (95% CI, 1.47 to 21.4 mg/dL). For treatment, adding regular insulin to TPN has been a successful strategy to control hyperglycemia, and recommended formulas for calculating dosing are available [76].

Management of hyperglycemia associated with continuous enteral feedings has proven challenging, and few studies are available. However, one was a randomized controlled trial conducted by Korytkowski et al. [77]. For this trial, a regimen of sliding-scale regular insulin alone was compared with one with sliding-scale regular insulin and glargine, with 25 inpatients randomized to each group. Although glycemic control was similar between the two groups, 12 patients receiving only sliding-scale regular insulin required the addition of NPH insulin because of persistent hyperglycemia, an intervention not needed among any of those in the group also receiving glargine. Total daily insulin doses were similar between the groups, as was frequency of hypoglycemia. These results support the role of longer-acting
basal insulin in the management of blood glucose levels among those patients receiving enteral feeding.

Another common factor complicating management of blood sugar among hospitalized patients is the prevalent use of glucocorticoids as treatment of a host of conditions known to be associated with hyperglycemia even among those without diabetes [78, 79]. To better characterize the insulin needs of this population, Spanakis et al. [80] conducted a chart review of 58 hospitalized patients with diabetes and found that, independent of age, race, body weight, renal function, or disease type, among several other variables, over half the patients remained hyperglycemic throughout their admission (n = 38). Those patients that did achieve normoglycemia had similar requirements for basal insulin as those who remained hyperglycemic (23.6 vs 20.1 U, respectively; P = 0.35). However, their nutritional insulin requirements were significantly higher (45.5 vs 20.1 U, P < 0.001), with lower correction insulin needs (5.8 vs 13.0 U, P < 0.001) than their hyperglycemia counterparts, respectively. Overall, their total daily doses of insulin were similar per kilogram between the two groups. Although limited by sample size, and because formal insulin dosing studies have not yet been performed, these findings do suggest nutritional insulin, as opposed to correction, should be made a priority when determining regimens for glucose management in patients on glucocorticoid therapy.

9. Moving Forward

Current guidelines based on studies presented here suggest maintaining fasting glucose values in the 100 to 140 mg/dL range and nonfasting levels <180 mg/dL [1]. Although the clinical impact of hyperglycemia among hospitalized patients has been well established, with multiple studies demonstrating increased morbidity and mortality [12, 81–83], the optimal medical management of diabetes in the inpatient setting has been extensively studied, but not yet definitively established [1, 2, 6, 84]. Insulin is still considered the mainstay of treatment of inpatient glucose control [85], and several trials have been conducted evaluating different regimens, with most data supporting the use of basal insulin (either analog or human) along with either prandial and correctional boluses compared with sliding scale only as described in the Basal Plus trial [7, 36, 37, 43]. More data are needed, however, looking at the clinical outcomes for insulin therapy, including patients without known diabetes. Given the known association of insulin with hypoglycemia, and the detrimental effect such episodes have on morbidity and mortality [44, 86], along with concerns regarding the rigorous blood sugar monitoring and dose adjustments required with insulin therapy [74], the utility of insulin alternatives has been investigated. Metformin, sulfonylureas, and thiazolidinediones have a number of contraindications to use, which often limit their utility in the inpatient setting with critically ill patients [56–58]. Incretin-based therapies have demonstrated promising results toward glycemic control without associated hypoglycemia, and further randomized controlled trials, specifically looking at the role of GLP-1 receptor agonist therapy, are warranted [62, 64, 73, 74, 85, 87, 88]. Thus far, however, there are no long-term data regarding the safety of incretin-based treatment. This raises the question of how effectively risk-benefit ratios can be compared between this therapy and insulin, which benefits from decades of safety data. Given the known negative impact of hypoglycemia and demonstrated association of hypoglycemia with insulin, there is an increased urgency to exploring this question.

One approach to achieving target glycemic control that is gaining attention is an automated closed-loop system for insulin delivery. Also known as the artificial pancreas, this delivery system uses a computerized algorithm by which insulin is either increased or decreased according to subcutaneous glucose sensors. Thabit et al. [89] investigated the safety and efficacy of this system compared with traditional subcutaneous insulin delivery in a 2017 controlled trial. For this study, 40 general ward inpatients with type 2 diabetes on insulin therapy were randomized on a 1:1 basis to treatment with the closed-loop insulin delivery system or conventional therapy according to local clinical guidelines. After a 72-hour period, 59.8% of time in the closed-loop system was spent in the target glucose range (100 to 180 mg/dL)
compared with 38.1% in the conventional control group. This led study investigators to conclude that the artificial pancreas was indeed a safe and effective alternative to traditional subcutaneous therapy among noncritically ill inpatients with type 2 diabetes receiving insulin; however, additional factors warrant consideration before translating these findings to a more realistic clinical setting. As described in an editorial response by Rayman [90], barriers to applying the closed-loop system to inpatient practice include limited familiarity among health care professionals with this intervention and potential safety issues that may arise with larger populations and over a longer period of time. Nevertheless, this trial serves as another example of the promising trajectory of inpatient diabetes management, and the value in continuing to investigate additional and alternative approaches to our traditional approach with insulin.

Acknowledgments

Address all correspondence to: Tina Gupta, MD, Division of Endocrinology, Diabetes & Hypertension, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115. E-mail: tgupta2@partners.org.

Disclosure Summary: The authors have nothing to disclose.

References and Notes

1. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Bergh G; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(1):16–38.
2. Sawin G, Shaughnessy AF. Glucose control in hospitalized patients. Am Fam Physician. 2010;81(9):1121–1124.
3. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131.
4. Kerby JD, Griffin RL, MacLennan P, Rue LW III. Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma. Ann Surg. 2012;256(3):446–452.
5. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23):3078–3086.
6. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch IB; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals [published corrections appears in Diabetes Care. 2004;27(3):553–591]. Diabetes Care. 2004;27(2):553–591.
7. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–261.
8. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355(18):1903–1911.
9. Finfer S, Heritier S; NICE Study Management Committee and SUGAR Study Executive Committee. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Crit Care Resusc. 2009;11(1):46–57.
10. Kitabchi AE, Freire AX, Umpierrez GE. Evidence for strict inpatient blood glucose control: time to revise glycemic goals in hospitalized patients. Metabolism. 2008;57(1):116–120.
11. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–1297.
12. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–982.
13. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet*. 2000; 355(9206):773–778.

14. King JT, Jr, Goulet JL, Perkal MF, Rosenthal RA. Glycemic control and infections in patients with diabetes undergoing noncardiac surgery. *Ann Surg*. 2011;253(1):158–165.

15. Schmelz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, O’Shea-Mahler E, Johnson D, Henske J, McCarthy PM, Gleason TG, McGee EC, Molitch ME. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. *Diabetes Care*. 2007;30(4):823–828.

16. Hruska LA, Smith JM, Hendy MP, Fritz VL, McAdams S. Continuous insulin infusion reduces infectious complications in diabetics following coronary surgery. *J Card Surg*. 2005;20(5):403–407.

17. Noordzij PG, Boersma E, Schreiner F, Kertai MD, Feringa HH, Dunkelgrun M, Bax JJ, Klein J, Poldermans D. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. *Eur J Endocrinol*. 2007;156(1):137–142.

18. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. *N Engl J Med*. 2001;345(19):1359–1367.

19. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2003;125(5):1007–1021.

20. Frisch A, Chandra P, Smiley D, Feng L, Rizzo M, Gatcliffe C, Hudson M, Mendoza J, Johnson R, Lin E, Umpierrez GE. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. *Diabetes Care*. 2010;33(8):1783–1788.

21. Wang R, Panizales MT, Hudson MS, Rogers SO, Schnipper JL. Preoperative glucose as a screening tool in patients without diabetes. *J Surg Res*. 2014;186(1):371–378.

22. Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. *J Vasc Surg*. 1998;28(4):687–694.

23. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davi G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. *J Am Coll Cardiol*. 2003;41(6):1013–1020.

24. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycaemia: a prothrombotic factor? *J Thromb Haemost*. 2010;8(8):1663–1669.

25. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HA. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. *Circulation*. 2008;118(9):968–976.

26. Xie J, Cui K, Hao H, Zhang Y, Lin H, Chen Z, Huang X, Cao S, Liao W, Bin J, Kitakaze M, Liao Y. Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation. *Cardiovasc Diabetol*. 2016;15(1):136.

27. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. *BMJ*. 1999;314(7093):1512–1515.

28. Marano L, Bestetti A, Lomuscio A, Tagliabue L, Castini D, Tarricone D, Dario P, Tarolo GL, Fiorentini C. Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. *Acta Cardiol*. 2000;55(1):9–15.

29. Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG, Grey CS. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). *Stroke*. 1999;30(4):793–799.

30. Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG, Grey CS. Blood pressure response to glucose potassium insulin therapy in patients with acute stroke with mild to moderate hyperglycemia. *J Neurol Neurosurg Psychiatry*. 2001;70(3):401–404.

31. Guazzi M, Brambilla R, De Vita S, Guazzi MD. Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. *Am J Respir Crit Care Med*. 2002;166(7):978–982.

32. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. *Diabetes Metab Res Rev*. 2016;32(6):478–496.

33. Zenari L, Marangoni A. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? *Diabetes Obes Metab*. 2013;15(Suppl 2):17–25.
34. Valgardson JD, Merino M, Redgrave J, Hudson JI, Hudson MS. Effectiveness of inpatient insulin order sets using human insulins in noncritically ill patients in a rural hospital. *Endocr Pract.* 2015;21(7):794–806.

35. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. *Arch Intern Med.* 1997;157(5):545–552.

36. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). *Diabetes Care.* 2007;30(9):2181–2186.

37. Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, Jacobs S, Rizzo M, Peng L, Reyes D, Pinzon I, Fereira ME, Hunt V, Gore A, Toyoshima MT, Fonseca VA. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. *Diabetes Care.* 2013;36(8):2169–2174.

38. Meyfroidt G, Keenan DM, Wang X, Wouters PJ, Veldhuis J, Van den Berghe G. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. *Crit Care Med.* 2010;38(4):1021–1029.

39. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. *Anesthesiology.* 2006;105(2):244–252.

40. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. *Crit Care Med.* 2008;36(11):3008–3013.

41. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. *Diabetes.* 1970;19(9):644–655.

42. Haw JS, Farrokhki F, Smiley D, Peng L, Reyes D, Newton C, Pasquel FJ, Vellanki P, Umpierrez GE. Comparison of basal insulin regimens on glycemic variability in non-critically ill patients with type 2 diabetes. *Endocr Pract.* 2015;21(12):1333–1343.

43. Umpierrez GE, Hor T, Smiley D, Tempioni A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2009;94(2):564–569.

44. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. *Diabetes Care.* 2009;32(7):1153–1157.

45. Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients. Causes and outcomes. *N Engl J Med.* 1986;315(20):1245–1250.

46. Kagnansky N, Levy S, Rimon E, Ciojocaru L, Fridman A, Ozer Z, Knobler H. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. *Arch Intern Med.* 2003;163(15):1825–1829.

47. Mortensen EM, Garcia S, Leykum L, Nakashima B, Restrepo MI, Anzueto A. Association of hypoglycemia with mortality for subjects hospitalized with pneumonia. *Am J Med Sci.* 2010;339(3):239–243.

48. Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. *Diabetes Care.* 2008;31(6):1222–1223.

49. O’Keefe JH, Abuannadi M, Lavin CJ, Bell DS. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. *Mayo Clin Proc.* 2011;86(2):128–138.

50. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Duld RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Sperl-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ.* 2010;340:b4909.

51. Kosiбород М, Инзуци SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, Spertus JA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *JAMA.* 2009;301(15):1556–1564.

52. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengepe AP, Marre M, Heller S; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med.* 2010;363(15):1410–1418.

53. Rajendran R, Rayman G. Serious harm from inpatient hypoglycaemia: a survey of hospitals in the UK. *Diabet Med.* 2014;31(10):1218–1221.

54. Garg R, Hurwitz S, Turchin A, Trivedi A. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients. *Diabetes Care.* 2013;36(5):1107–1110.

55. Rubin DJ, Rybin D, Doros G, McDonell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. *Diabetes Care.* 2011;34(8):1723–1728.

56. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of
hypercglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2009;32(1):193–203.

57. Fowler M. Diabetes Treatment, Part 2: Oral agents for glycemnic management. *Clin Diabetes*. 2007; 25(4):131–134.

58. Bailey CJ, Turner RC. Metformin. *N Engl J Med*. 1996;334(9):574–579.

59. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J; CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol*. 2006; 98(6A):59K–77K.

60. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, Farrokhii F, Peng L, Reyes D, Lathkar-Pradhan S, Pasquale Safety and efficacy of sitaglutn therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. *Diabetes Care*. 2013;36(11):3430–3435.

61. Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, Peng L, Hodish I, Bodnar T, Wesorick D, Balakrishnan V, Osei K, Umpierrez GE. Efficacy of sitaglutn for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. *Lancet Diabetes Endocrinol*. 2017;5(2):125–133.

62. Schwartz S, DeFronzo RA. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: the time has come for GLP-1 receptor agonists! *Diabetes Care*. 2013;36(7):2107–2111.

63. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? *Diabetologia*. 2011;54(1):10–18.

64. Schwartz SS, DeFronzo RA, Umpierrez GE. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. *Postgrad Med*. 2015;127(2):251–257.

65. Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG. The use of exenatide in severely burned pediatric patients. *Crit Care*. 2010;14(4):R153.

66. Kohl BA, Hammond MS, Cucchiara AJ, Ochroch EA. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study. *J Cardiothorac Vasc Anesth*. 2014;28(3):618–625.

67. Abuannadi M, Kosiborod M, Riggs L, House JA, Hammond MS, Kennedy KD, Marso SP. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. *Endocr Pract*. 2013;19(1):81–90.

68. Müssig K, Oncü A, Lindauer P, Heininger A, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. *Am J Cardiol*. 2008;102(5):646–647.

69. Sokos GG, Bolukoglu H, German J, Hentosa T, Magovern GJ, Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. *Am J Cardiol*. 2007;100(5):824–829.

70. Thrailikhott I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. *Diab Vasc Dis Res*. 2004;1(1):40–43.

71. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. *Am J Physiol Endocrinol Metab*. 2004;287(6):E1209–E1215.

72. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation*. 2004;109(8):962–965.

73. Halbirk M, Norrelund H, Møller N, Holst JJ, Schmitz O, Nielsen K, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Bøtker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. *Am J Physiol Heart Circ Physiol*. 2010;298(3):H1096–H1102.

74. Bode, B., Amin A. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. *Hosp Pract*. 2009;37(1):7–21.

75. Olveira G, Tapia MJ, Ocón J, Cabrejas-Gómez C, Ballesteros-Pomar MD, Vidal-Casariego A, Arriaza-Irigoyen C, Olivares J, Conde-García MdeC, García-Manzanares A, Botella-Romero F, Quiroz-Toboso RP, Cabrero Iz, Matia P, Chicharro L, Burgos R, Pujante P, Ferrer M, Zugasti A, Prieto J, Diéguez M, Carrera MJ, Vila-Bundo A, Urgelés JR, Aragón-Valera C, Rovira A, Béretón I, García-Peris P, Muñoz-Garach A, Márquez E, Del Olmo D, Pereira JL, Tous MC; Study Group of Hyperglycemia in Parenteral
Nutrition: Nutrition Area of the Spanish Society of Endocrinology and Nutrition (SEEN). Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study). *Diabetes Care*. 2013;36(5):1061–1066.

76. Cheng AY. Achieving glycemic control in special populations in hospital: perspectives in practice. *Can J Diabetes*. 2014;38(2):134–138.

77. Korytkowski MT, Salata Rj, Koerbel GL, Selzter F, Karslioglu E, Idriss AM, Lee KK, Moser AJ, Toledo FG. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. *Diabetes Care*. 2009;32(4):594–596.

78. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. *Endocr Pract*. 2009;15(5):469–474.

79. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. *Endocr Pract*. 2006;12(4):358–362.

80. Spanakis EK, Shah N, Malhotra K, Kemmerer T, Yeh HC, Hill Golden S. Insulin requirements in non-critically ill hospitalized patients with diabetes and steroid-induced hyperglycemia. *Hosp Pract*. 2014;42(2):23–30.

81. Moghissi ES. Reexamining the evidence for inpatient glucose control: new recommendations for glycemic targets. *Am J Health Syst Pharm*. 2010;67(16Suppl 8):S3–S8.

82. Moghissi ES. Addressing hyperglycemia from hospital admission to discharge. *Curr Med Res Opin*. 2010;26(3):589–598.

83. Hassan E. Hyperglycemia management in the hospital setting. *Am J Health Syst Pharm*. 2007;64(10Suppl 6):S9–S14.

84. Peterson G. Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia. *Hosp Pract*. 2011;39(4):87–95.

85. Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment. *Diabetes Care*. 2013;36(7):2112–2117.

86. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. *Endocrinol Metab Clin North Am*. 2012;41(1):175–201.

87. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. *Am J Med*. 2011;124(1Suppl S3):S35–S53.

88. Umpierrez GE, Schwartz S. Use of incretin-based therapy in hospitalized patients with hyperglycemia. *Endocr Pract*. 2014;20(9):933–944.

89. Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. *Lancet Diabetes Endocrinol*. 2017;5(2):117–124.

90. Rayman G. Closer to closing the loop on inpatient glycaemia. *Lancet Diabetes Endocrinol*. 2017;5(2):81–83.